Tao Lu

Tao Lu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JZJu Zhou
Ju Zhou
SISaber Imani
Saber Imani
MSmarzieh dehghan shasaltaneh
marzieh dehghan shasaltaneh
SLShuguang Liu
Shuguang Liu
TLTao Lu
Tao Lu
JFJunjiang Fu
Junjiang Fu

6 February 2023 in Cancer Reports
Verified
Journal Article
Open access
FBFei Bai
Fei Bai
QDQian Du
Qian Du
QZQingliang Zou
Qingliang Zou
LXLin Xu
Lin Xu
WDWei Dong
Wei Dong
TLTao Lu
Tao Lu
Background: Colorectal cancer (CRC) is a deadly and commonly diagnosed cancer. Cell‐free circulating tumor DNAs (ctDNA) have been used in the diagnosis and treatment of CRC, but there are open questions about the relationship between ctDNAs and CRC. Although mutations of genes detected by ctDNA in CRC have been studied, the quantitative relationship between ctDNA mutations and ctDNA concentration has not been addressed.Aims: We hypothesized that there was an association between mutations of genes identified in ctDNAs and ctDNA concentration. His study examined this association in a population of CRC patients.Methods: In 85 CRC patients, we sampled 282 mutations in 36 genes and conducted an association study based on a Random forest model between mutations and ctDNA concentrations in all patients.Results: This association study showed that mutations on five genes, ALK, PMS2, KDR, MAP2K1, and MSH2, were associated with the ctDNA concentrations in CRC patients’ blood samples. Because ctDNA mutations correlate with ctDNA level, we can infer the tumor burden or tumor size from ctDNA mutations, as well as the survival time for prognosis.Conclusion: Our findings shed light on the associations between mutations of genes identified in ctDNAs and ctDNA concentration in the blood of CRC patients. This discovery provides information regarding the tumor burden or tumor size based on ctDNA mutations.